InvestmentApr 30, 2026, 04:27 PM
CMND Increases Convertible Note Capacity by $10M; Board Changes
AI Summary
Clearmind Medicine Inc. announced an amendment to its securities purchase agreements, increasing the capacity for future issuances of convertible promissory notes by $10,000,000. This provides the company with additional funding flexibility. Concurrently, the company reported significant changes to its Board of Directors, including the resignation of Chairman Mr. Amitay Weiss and the appointment of Ms. Hila Kiron-Revach as the new chairperson. Additionally, Mr. Asaf Itzhaik was appointed to key board committees, and the independence of several directors was confirmed.
Key Highlights
- CMND increased the capacity for future issuances of convertible promissory notes by $10,000,000.
- The total available capacity for additional Promissory Notes is now $10,000,000.
- Mr. Amitay Weiss resigned as chairman of the Board, effective April 26, 2026.
- Ms. Hila Kiron-Revach was appointed as the new chairperson of the Board on April 27, 2026.
- Mr. Asaf Itzhaik was appointed to the compensation committee and nominating and corporate governance committee.
- Ms. Hila Kiron-Revach, Mr. Yehonatan Shachar, and Mr. Asaf Itzhaik were determined to be independent directors.